Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 386, Issue 1, pp 51–59 | Cite as

The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia

  • Ana T. Guerrero
  • Ana C. Zaperlon
  • Silvio M. Vieira
  • Larissa G. Pinto
  • Sérgio H. Ferreira
  • Fernando Q. Cunha
  • Waldiceu A. VerriJr.Email author
  • Thiago M. CunhaEmail author
Original Article


Platelet-activating factor (PAF) and its receptor (PAFR) have been shown to be involved in several inflammatory events, including neutrophil chemoattraction and nociception. The present study addressed the role of PAF in the genesis of articular hyperalgesia in a model of joint inflammation. Zymosan-induced articular hyperalgesia, oedema and neutrophil migration were dose-dependently reduced following pretreatment with selective PAFR antagonists, UK74505 (5, 10 and 20 mg/kg) and PCA4248 (3, 10, 30 mg/kg). These parameters were also reduced in PAF receptor-deficient mice (PAFR−/−). The hyperalgesic action of PAF was further confirmed by the demonstration that joint injection of PAF induces a dose- (0.3, 1 and 3 μg/joint), time- and PAFR-dependent articular hyperalgesia and oedema. The PAF hyperalgesic mechanisms were dependent on prostaglandins, leukotrienes and neutrophils, as PAF-induced articular hyperalgesia was inhibited by indomethacin (COX inhibitor), MK886 (leukotrienes synthesis inhibitor) or fucoidan (leukocyte rolling inhibitor). Furthermore, PAF-induced hyperalgesia was reduced in 5-lypoxigenase-null mice. In corroboration of these findings, intra-articular injection of PAF promotes the production of LTB4 as well as the recruitment of neutrophils to the joint. These results suggest that PAF may participate in the cascade of events involved in the genesis of articular inflammatory hyperalgesia via stimulation of prostaglandins, leukotrienes and neutrophil migration. Finally, targeting PAF action (e.g., with a PAFR antagonist) might provide a useful therapeutic approach to inhibit articular inflammatory hyperalgesia.


Zymosan Joint pain Arthritis Hyperalgesia PAF Neutrophils 



This work was supported by grants from Fundacão de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Pesquisa (CNPq) in Brazil. We thank the excellent technical assistance of Ana K. dos Santos, Giuliana B. Francisco, Ieda Regina dos Santos Schivo and Sérgio R. Rosa.


  1. Benveniste J, Roubin R, Chignard M, Jouvin-march E, LeCouedic J (1982) Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. Agents Actions 12:711–713PubMedCrossRefGoogle Scholar
  2. Bisgaard H, Kristensen JK (1985) Leukotriene B4 produces hyperalgesia in humans. Prostaglandins 30:791–797PubMedGoogle Scholar
  3. Bonnet J, Loiseau AM, Orvoen M, Bessin P (1981) Platelet-activating factor acether (PAF-acether) involvement in acute inflammatory and pain processes. Agents Actions 11:559–562PubMedCrossRefGoogle Scholar
  4. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206–209PubMedCrossRefGoogle Scholar
  5. Braquet P, Rola-Pleszczynski M (1987) Platelet-activating factor and cellular immune responses. Immunol Today 8:345–352CrossRefGoogle Scholar
  6. Cunha TM, Verri WA Jr, Vivancos GG, Moreira IF, Reis S, Parada CA, Cunha FQ, Ferreira SH (2004) An electronic pressure-meter nociception paw test for mice. Braz J Med Biol Res 37:401–407PubMedCrossRefGoogle Scholar
  7. Cunha TM, Verri WA Jr, Schivo IR, Napimoga MH, Parada CA, Poole S, Teixeira MM, Ferreira SH, Cunha FQ (2008) Crucial role of neutrophils in the development of mechanical inflammatory hypernociception. J Leukoc Biol 83:824–832PubMedCrossRefGoogle Scholar
  8. Czarnetzki BM, Benveniste J (1981a) Effect of 1-O-octadecyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) on leukocytes: I. Analysis of the in vitro migration of human neutrophils. Chem Phys Lipids 29:317–326PubMedCrossRefGoogle Scholar
  9. Czarnetzki BM, Benveniste J (1981b) Effect of synthetic PAF-acether on human neutrophil function. Agents Actions 11:549–550PubMedCrossRefGoogle Scholar
  10. Gaudreault E, Stankova J, Rola-Pleszczynski M (2005) Involvement of leukotriene B4 receptor 1 signaling in platelet-activating factor-mediated neutrophil degranulation and chemotaxis. Prostaglandins Other Lipid Mediat 75:25–34PubMedCrossRefGoogle Scholar
  11. Gegout P, Gillet P, Chevrier D, Guingamp C, Terlain B, Netter P (1994) Characterization of zymosan-induced arthritis in the rat: effects on joint inflammation and cartilage metabolism. Life Sci 55:321–326CrossRefGoogle Scholar
  12. Guerrero AT, Verri WA Jr, Cunha TM, Silva TA, Rocha FA, Ferreira SH, Cunha FQ, Parada CA (2006) Hypernociception elicited by tibio-tarsal joint flexion in mice: a novel experimental arthritis model for pharmacological screening. Pharmacol Biochem Behav 84:244–251PubMedCrossRefGoogle Scholar
  13. Guerrero AT, Verri WA Jr, Cunha TM, Silva TA, Schivo IR, Dal-Secco D, Canetti C, Rocha FA, Parada CA, Cunha FQ, Ferreira SH (2008) Involvement of LTB4 in zymosan-induced joint nociception in mice: participation of neutrophils and PGE2. J Leukoc Biol 83:122–130PubMedCrossRefGoogle Scholar
  14. Hasegawa S, Kohro Y, Shiratori M, Ishii S, Shimizu T, Tsuda M, Inoue K (2010) Role of PAF receptor in proinflammatory cytokine expression in the dorsal root ganglion and tactile allodynia in a rodent model of neuropathic pain. PLoS One 5:e10467PubMedCrossRefGoogle Scholar
  15. Hilliquin P, Guinot P, Chermat-Izard V, Puechal X, Menkes CJ (1995a) Production of PAF –acether by synovial fluid neutrophils in rheumatoid arthritis. Inflamm Res 44:313–316PubMedCrossRefGoogle Scholar
  16. Hilliquin P, Guinot P, Chermat-Izard V, Puechal X, Menkes CJ (1995b) Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol 22:1651–1654PubMedGoogle Scholar
  17. Hopkins NK, Schaub RG, Gorman RR (1984) Acetyl glyceryl ether phosphorylcholine (PAF-acether) and leukotriene B4-mediated neutrophil chemotaxis through an intact endothelial cell monolayer. Biochim Biophys Acta 805:30–36PubMedCrossRefGoogle Scholar
  18. Howat D, Desa F, Chander C, Moore A, Willoughby DA (1990) The synergism between platelet-activating factor and interleukin-1 on cartilage breakdown. J Lipid Med 2:5143–5149Google Scholar
  19. Hwang SB, Lam MH, Pong SS (1986) Ionic and GTP regulation of platelet-activating factor to receptors and platelet-activating factor-induced activation of GTPase in rabbit platelet membranes. J Biol Chem 261:532–537PubMedGoogle Scholar
  20. Ishii S, Nagase T, Shimizu T (2002) Platelet-activating factor receptor. Prostaglandins Other Lipid Mediat 68–69:599–609PubMedCrossRefGoogle Scholar
  21. Keystone EC, Schorlemmer HU, Pope C, Allison AC (1977) Zymosan-induced arthritis: a model of chonic proliferative arthritis following activation of the alternative pathway of complement. Arthritis Rheum 20:1396–1401PubMedCrossRefGoogle Scholar
  22. Kuitert LM, Angus RM, Barnes NC, Barnes PJ, Bone MF, Chung KF, Fairfax AJ, Higenbotham TW, O'Connor BJ, Piotrowska B et al (1995) Effect of a novel potent platelet-activating factor antagonist, modipafant, in clinical asthma. Am J Respir Crit Care Med 151:1331–1335PubMedGoogle Scholar
  23. Levine JD, Lau W, Kwiat G, Goetzl EJ (1984) Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 225:743–745PubMedCrossRefGoogle Scholar
  24. Ley K, Linnemann G, Meinen M, Stoolman LM, Gaehtgens P (1993) Fucoidin, but not yeast polyphosphomannan PPME, inhibits leukocyte rolling in venules of the rat mesentery. Blood 81:177–185PubMedGoogle Scholar
  25. Lynch JM, Lofner GZ, Betz SJ, Henson PM (1979) The release of a platelet-activating factor by stimulated rabbit neutrophils. J Immun 123:1219–1226PubMedGoogle Scholar
  26. Miguélez R, Palácios I, Navarro FA, Gutierrez S, Sanchez-Pernaute O, Egido J, Gonzalez E, Herrero-Beaumont G (1996) Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. J Lipid Mediat Cell Signal 13:35–49PubMedCrossRefGoogle Scholar
  27. Millan MJ (1999) The induction of pain: an integrative review. Prog Neurobiol 57:1–164PubMedCrossRefGoogle Scholar
  28. Morita K, Morioka N, Abdin J, Kitayama S, Nakata Y, Dohi T (2004) Development of tactile allodynia and thermal hyperalgesia by intrathecally administered platelet-activating factor in mice. Pain 111:351–359PubMedCrossRefGoogle Scholar
  29. Okubo M, Yamanaka H, Kobayashi K, Kanda H, Dai Y, Noguchi K (2012) Up-regulation of platelet-activating factor synthases and its receptor in spinal cord contribute to development of neuropathic pain following peripheral nerve injury. Mol Pain. doi: 10.1186/1744-8069-8-8
  30. Palacios I, Miguélez R, Sánchez-Pernaute O, Gutierrez S, Egido J, Herrero-Beaumont G (1999) A platelet activating factor receptor antagonist prevents the development of chronic arthritis in mice. J Rheumatol 26:1080–1086PubMedGoogle Scholar
  31. Pettipher ER, Higgs GA, Henderson B (1987) PAF-acether in chronic arthritis. Agents Actions 21:98–103PubMedCrossRefGoogle Scholar
  32. Roubin R, Mencia-Huerta JM, Benveniste J (1982) Release of platelet-activating factor (PAF-acether) and leukotrienes C and D from inflammatory macrophages. Eur J Immunol 12:141–146PubMedCrossRefGoogle Scholar
  33. Shio MT, Ribeiro-Dias F, Timenetsky J, Jancar S (2004) PAF is involved in the Mycoplasma arthritidis superantigen-triggering pathway for iNOS and COX-2 expression in murine peritoneal cells. Exp Cell Res 298:296–304PubMedCrossRefGoogle Scholar
  34. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM (2003) Platelet activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 40:643–672PubMedCrossRefGoogle Scholar
  35. Ting E, Guerrero AT, Cunha TM, Verri WA Jr, Taylor SM, Woodruff TM, Cunha FQ, Ferreira SH (2008) Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol 153:1043–1053PubMedCrossRefGoogle Scholar
  36. Tsuda M, Ishii S, Masuda T, Hasegawa S, Nakamura K, Nagata K, Yamashita T, Furue H, Tozaki-Saitoh H, Yoshimura M, Koizumi S, Shimizu T, Inoue K (2007) Reduced pain behaviors and extracellular signal-related protein kinase activation in primary sensory neurons by peripheral tissue injury in mice lacking platelet-activating factor receptor. J Neurochem 102:1658–1668PubMedCrossRefGoogle Scholar
  37. Vargaftig BB, Ferreira SH (1981) Blockade of the inflammatory effects of platelet-activating factor by cyclo-oxygenase inhibitors. Braz J Med Biol Res 14:187–189PubMedGoogle Scholar
  38. Verri WA Jr, Cunha TM, Magro DA, Guerrero AT, Vieira SM, Carregaro V, Souza GR, Henriques MG, Ferreira SH, Cunha FQ (2009) Targeting endothelin ETA and ETB receptors inhibits antigen-induced neutrophil migration and mechanical hypernociception in mice. Naunyn-Schmiedebergs Arch Pharmacol 379:271–279PubMedCrossRefGoogle Scholar
  39. Wang HY, Yue TL, Firestein G, Friedman E (1994) Platelet-activating factor: diminished acetylcholine release from rat brain slices is mediated by a Gi protein. J Neurochem 63:1720–1725PubMedCrossRefGoogle Scholar
  40. Zarco P, Maestre C, Herrero-Beaumont G, González E, Garcia-Hoyo R, Navarro FJ, Braquet P, Egido J (1992) Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. Clin Exp Immunol 88:318–323PubMedCrossRefGoogle Scholar
  41. Zhang Q, Sitzman LA, Al-Hassani M, Cai S, Pollok KE, Travers JB, Hingtgen CM (2009) Involvement of platelet-activating factor in ultraviolet B-induced hyperalgesia. J Invest Dermatol 129:167–174Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Ana T. Guerrero
    • 1
    • 2
  • Ana C. Zaperlon
    • 3
  • Silvio M. Vieira
    • 1
    • 4
  • Larissa G. Pinto
    • 1
  • Sérgio H. Ferreira
    • 1
  • Fernando Q. Cunha
    • 1
  • Waldiceu A. VerriJr.
    • 1
    • 3
    Email author
  • Thiago M. Cunha
    • 1
    Email author
  1. 1.Department of Pharmacology, School of Medicine of Ribeirão PretoUniversity of São PauloRibeirão PretoBrazil
  2. 2.Fundação Oswaldo Cruz (FIOCRUZ), Mato Grosso do SulCampo GrandeBrazil
  3. 3.Departamento de Patologia, Centro de Ciências BiológicasUniversidade Estadual de LondrinaLondrinaBrazil
  4. 4.Departamento de Patologia, Centro de Ciências BiológicasUniversidade Estadual de LondrinalLondrinaBrazil

Personalised recommendations